Barclays Boosts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $25.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by Barclays from $22.00 to $25.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other research firms also recently issued reports on TEVA. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $17.90 on Wednesday. The company has a market cap of $20.27 billion, a P/E ratio of -43.66, a P/E/G ratio of 1.32 and a beta of 0.88. The firm’s 50 day moving average is $18.01 and its two-hundred day moving average is $16.78. Teva Pharmaceutical Industries has a fifty-two week low of $8.10 and a fifty-two week high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TEVA. Quadrature Capital Ltd bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $203,000. Park Avenue Securities LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $248,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 30.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock worth $2,909,000 after acquiring an additional 47,954 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 36,753 shares of the company’s stock valued at $519,000 after acquiring an additional 7,763 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Teva Pharmaceutical Industries by 1.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,159,333 shares of the company’s stock valued at $30,468,000 after acquiring an additional 27,713 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.